22 citations
,
November 2002 in “Clinical journal of oncology nursing” Arsenic trioxide effectively treats relapsed acute promyelocytic leukemia with manageable side effects.
7 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
October 2024 in “Canadian Journal of Health Technologies” Olumiant should be covered for severe alopecia areata if certain conditions are met.
February 2026 in “Molecules” BBR-SA nanomedicine is a safe and effective treatment for breast cancer.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
5 citations
,
April 2025 in “Journal of Cosmetic Dermatology” Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
2 citations
,
May 2023 in “Journal of Immunotherapy” Sintilimab treatment caused hair loss but led to complete tumor remission.
9 citations
,
August 2018 in “JAAD Case Reports” Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
October 2025 in “International Journal of Risk & Safety in Medicine” Oral tofacitinib successfully treated a girl's severe skin and hair conditions.
Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
1 citations
,
April 2010 in “Cancer Research” WYE-130600 may cause skin thickening and irritation.
5 citations
,
January 2022 in “Dermatology Reports” Tofacitinib treatment for hair loss may worsen acne.
65 citations
,
February 2011 in “Molecular cancer therapeutics” CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
June 2024 in “Poster presentations” Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.
28 citations
,
July 2017 in “Expert Review of Anticancer Therapy” Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
44 citations
,
August 1996 in “Drugs & Aging” Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.
3 citations
,
July 2025 in “International Immunopharmacology”
September 2023 in “Drugs in context” Baricitinib is a promising treatment for alopecia areata.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
1 citations
,
August 2022 in “Journal of Dermatology and Dermatologic Surgery” A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.
Baricitinib showed mixed results in treating alopecia areata in children, with some improvement but also side effects.
2 citations
,
July 2023 in “JAAD Case Reports” A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.
9 citations
,
January 2023 in “Dermatology and therapy” A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
October 2021 in “International journal of basic and clinical pharmacology” Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
December 2025 in “Педиатрическая фармакология” Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.
6 citations
,
May 2024 in “JAAD Case Reports” Topical ruxolitinib cream may help treat frontal fibrosing alopecia.